Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2019
Message from the CEO
In our previous quarterly report we were able to announce that the first patient had been recruited in our clinical phase III-study. This study is operationally the most significant in IBT’s operations and therefore I choose to provide some detailed information regarding the study. The study is randomized, double blind and placebo controlled to evaluate the safety and efficacy of IBP-9414 with respect to the prevention of necrotizing enterocolitis and other clinically important aspects of feeding preterm babies.
Our assumptions regarding patient recruitment are based on experience from the concluded phase II study which IBT conducted at 15 clinics in the U.S. during 2017. We currently have approval for conducting the phase III study in France, Spain, The U.K., Hungary and the U.S. and have recruited patients in both Europe and in the U.S. As of the date of this report 37 centers of the 100 planned have been contracted and work is ongoing to contract more. We have not yet initiated recruitment in the UK, while in e.g. Spain recruitment is progressing above expectations at centers which have initiated recruitment.
Meetings held with study doctors during recent weeks have provided awareness of the difficulties of interpreting the inclusion and exclusion criteria described in the study protocol. Therefore, we revised and clarified these criteria during October rendering them more aligned with those used in our phase II study.
We are not satisfied that the study has had a slow start at certain clinical centers, but we also note that other centers are recruiting well, i.e. above expectations. We shall therefore further strengthen the clinical department at IBT in order to ensure that “best practice” is relayed from the centers with superior recruitment to those hospitals which have not initiated as planned. I expect the study to be concluded during 2021 based on the experience we gained from the phase II study. We will therefore further intensify our work with patient recruitment.
November 7, 2019
Chief Executive Officer
|Selected financial data|
|Operating profit/loss||-11 007||-7 683||-19 774||-15 541||-39 417|
|Result after tax, SEK||-10 538||-7 985||-18 786||-16 464||-40 607|
|Total assets||545 348||589 820||545 348||589 820||563 371|
|Cash flow for the period (SEK)||-34 064||-9 809||-42 755||406 210||381 544|
|Cash flow per share for the period (SEK)||-3.03||-0.87||-3.81||38.17||35.36|
|Cash||511 888||566 786||511 888||566 786||542 170|
|Earnings per share before and after dilution (SEK)||-0.94||-0.71||-1.67||-1.55||-3.76|
|Equity per share (SEK)||47.92||51.74||47.92||51.74||49.59|
|Equity ratio (%)||99%||98%||99%||98%||99%|
Significant events during the third quarter (Jul-Sep) 2019
• IBT announced on July 4 that the first patient had been recruited in the company’s pivotal clinical phase III-study, The Connection Study
Significant events during the reporting period (Jan-Sep) 2019
- IBT signed its first distribution agreement on March 5, 2019, for its product IBP-9414, with MegaPharm Ltd. for the Israeli market and the Palestinian Authority’s territories. The agreement gives MegaPharm exclusive rights to market and sell the product, if and when the product receives market approval. IBT’s share will, after an initial shorter period, account for 70% of revenues. IBT plans to open clinical trial centers for the pivotal phase III trial in the country. MegaPharm is already participating in this work as it is essential to engage “key opinion leaders” in the marketing of the product
- On May 19, 2019, we announced that IBT had responded satisfactorily to the comments that the FDA had regarding the study design. As a consequence of the FDA’s comments, an evaluation of the effects of IBP-9414 on the digestive system of premature infants in the forthcoming phase III study is now planned, as a serious medical problem for premature infants is that they cannot take up nourishment in an adequate way. The prior focus was solely prevention of NEC (necrotizing enterocolitis) that, in itself, is a terrible intestinal disease affecting premature infants and too often leads to fatal outcomes. Including another indication means having multiple independent endpoints which may increase the chances of success in the study and thus the market potential
- IBT’s IND-Application (Investigational New Drug) was approved in the USA and the clinical study has also been approved in the UK, France, Hungary and Spain
Significant events after the reporting period
• Lilian Wikström Ph.D. has requested to resign from the Board of Directors of IBT with immediate effect due to the risk of conflict of interest that has arisen in her role as CEO of KI Innovations AB
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of so called feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).
For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 70 670 1226
This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq Stockholm. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 CET on November 7, 2019.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Leasinvest Real Estate SCA: 2019 Bond Private Placement20.11.2019 19:30:00 CET | Press release
Bond private placement for an amount of EUR 100 million Leasinvest Real Estate SCA today successfully issued a 7-year private placement of bonds amounting to EUR 100 million, in denominations of EUR 100,000. The bonds offer a fixed annual coupon of 1.95% and have been placed with investors in Belgium, France and Luxembourg. BNP Paribas Fortis and Degroof Petercam were appointed as Global Coordinators of the transaction. BNP Paribas Fortis, Degroof Petercam and KBC acted as Joint Bookrunners of the transaction. The placement fits within Leasinvest Real Estate’s strategy to arrange financing sources best suited to carry out its investment strategy both through acquisitions and redevelopment of existing core assets. The proceeds will, amongst other things, serve to refinance the EUR 75 million public bond which matured on 9 October 2019 and will contribute to an increase of the average duration of the total debt of Leasinvest Real Estate and a diversification of its financing sources. MIC
IMCD expands Americas footprint by acquiring Colombian specialty distributor Unired Químicas20.11.2019 19:00:00 CET | Press release
ROTTERDAM, The Netherlands (20 November 2019) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of specialty chemicals and food ingredients, today announced that it has acquired 100% of the outstanding shares of the Colombia-based ingredient distributor, Unired Químicas SAS (“Unired”). With an office in Bogota, Colombia, Unired distributes specialty chemicals and ingredients to the pharmaceutical, food and personal care markets. In 2018, Unired generated a revenue of USD 8 million and has approximately 15 employees. The company will be fully integrated with IMCD’s organisation in 2020. Please find attached the full press release. Attachment PRESS RELEASE_IMCD expands Americas footprint by acquiring Colombian specialty distributor Unired Químicas
Agfa-Gevaert: Publication of a transparency notification (Axxioon) – Regulated information20.11.2019 17:40:00 CET | Press release
(Article 14 of the law of May 2, 2007 on the disclosure of significant shareholdings) Mortsel, Belgium – November 20, 2019 – 5.40 p.m. CET According to Agfa-Gevaert NV’s bylaws, the threshold as from which a shareholding needs to be disclosed, has been set at 3%, 5% and a multiple of 5%. In conformity with the Law of May 2, 2007 regarding the disclosure of significant shareholdings in listed companies, Agfa-Gevaert (Euronext: AGFB) discloses the following declaration: On November 19, 2019, Axxion S.A. has announced that as per November 15, 2019, it holds a stake in Agfa-Gevaert of 5,598,000 shares or 3.26% (denominator is 171,851,042), thus crossing the 3% threshold upwards. Notifications of important shareholdings to be made according to the Law of May 2, 2007 or Agfa-Gevaert NV’s bylaws, should be sent to email@example.com. About Agfa The Agfa-Gevaert Group develops, manufactures and distributes an extensive range of analogue and digital imaging systems and IT solutions, mainly
Notice on Convocation of Extraordinary General Meeting of Shareholders of AB Klaipedos nafta20.11.2019 15:02:00 CET | Press release
Notice is hereby given that on the initiative and by the resolution of the Board of AB Klaipedos Nafta, legal entity code 110648893, with the registered office at Burių str. 19, Klaipeda (hereinafter - the Company), Extraordinary General Meeting of Shareholders of the Company will be held on 12 December 2019 at 1:00 p.m. The meeting will be held in the Company’s office at Buriu str. 19, Klaipeda, in the administrative office of the Company (in the hall of the meeting on the 2nd floor). Agenda of the meeting: Regarding the approval of the additional decision of the Board of AB Klaipėdos nafta to pledge from 2025 all current and future amounts receivable (the Security Component) of the Company for the benefit of the Ministry of Finance of the Republic of Lithuania for the state guarantee granted by the Republic of Lithuania; Regarding the approval of the additional decision of the Board of AB Klaipėdos nafta to obtain and present up to EUR 20,000,000 (twenty million euros) annual bank gu
Åland Index Solutions - a game changer tackling climate crisis at every transaction20.11.2019 14:10:00 CET | Press release
Ålandsbanken Abp Pressrelease 20.11.2019 Åland Index Solutions - a game changer tackling climate crisis at every transaction Åland Index Solutions, a joint venture between Doconomy and Ålandsbanken, enables banks, payment providers and financial institutions to offer all customers transaction based impact calculations. Åland Index is the global index solution for CO2 emission calculations that guide consumers in their everyday consumption towards more sustainable choices. “With Åland Index Solutions we can engage all financial players in the fight against climate change. This collaboration is a milestone in creating a global standard for measuring the impact of consumption and totally changing the way we consume through connecting spending patterns with climate impact, says Nathalie Green CEO at Doconomy” The original Åland Index was developed in 2016 and the team has ever since been working to help consumers become aware of their impact on the planet. Åland Index is continuously being
Åland Index Solutions – en avgörande skillnad för banker som vill angripa klimatkrisen i varje transaktion20.11.2019 14:10:00 CET | Pressemelding
Ålandsbanken Abp Pressmeddelande 20.11.2019 Åland Index Solutions – en avgörande skillnad för banker som vill angripa klimatkrisen i varje transaktion Åland Index Solutions, ett samägt bolag mellan Doconomy och Ålandsbanken, skapar förutsättningar för banker, företag som erbjuder betaltjänster och finansiella institutioner att erbjuda sina kunder transaktionsbaserade påverkansberäkningar. Åland Index är det globala index för beräkningar av koldioxidutsläpp som hjälper individer ställa om sin konsumtion till att bli mer klimatmässigt uthållig. ”Med Åland Index Solutions kan vi aktivera alla finansiella aktörer i kampen mot klimatförändringarna. Samarbetet är en milstolpe i skapandet av en global standard för att mäta konsumtionens klimatpåverkan och genom att koppla samman konsumtionsmönster med påverkan, i grunden, förändra det sätt vi konsumerar på”, säger Nathalie Green, vd på Doconomy. Åland Index lanserades 2016 och utvecklingsteamet har sedan dess arbetat med att hjälpa konsumente